Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3′,5′-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5803-5806

  Venkatraman, Shankar ^a   Lebsack, Alec D ^a   Alves, Kenneth ^a   Gardner, Michael F ^a   James, Joyce ^a   Lingham, Russell B ^a   Maniar, Salony ^a   Mumford, Richard A ^a   Si, Qian ^a   Stock, Nicholas ^a   Treonze, Kelly M ^a   Wang, Bowei ^a   Zunic, Jasmine ^a   Munoz, Benito ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonist; Multiple scelerosis; VLA 4

Indexed keywords

AMINE; FLUORINE; MK 0617; N [N [(3 CYANOBENZENE)SULFONYL] 4 (3,3 DIFLUOROPIPERIDIN 1 YL)PROLYL] 4 [(3',5' DICHLORO ISONICOTINNOYL)AMINO]PHENYLALANINE; PROLINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ARTICLE; DRUG POTENCY; IN VITRO STUDY; NONHUMAN; RAT; RECEPTOR OCCUPANCY;

ADMINISTRATION, ORAL; ANIMALS; DIPEPTIDES; DRUG DISCOVERY; INTEGRIN ALPHA4BETA1; PHENYLALANINE; PRODRUGS; RATS;

RATTUS;

EID: 69949111765     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.111     Document Type: Article

References (20)

1. Hemler M.E., Elices M.J., Parker C., and Takada Y. Immunol. Rev. 114 (1990) 45
2. Elices M.J. Curr. Opin. Anti-infamm. Immunol. 1 (1999) 15
3. Kent S.J., Karlik S.J., Cannon C., Hines D.K., Yednock T.A., Fritz L.C., and Horner H.C. J. Neuroimmunol. 58 (1995) 1
4. Honey K. J. Clin. Invest. 118 (2008) 825
5. For Asthma see:. Sielszak M.W., Ahmed A., Cortes A., Lauredo I.T., Kim J., Pepinsky B., Beenjamin C.D., Leone D.R., Lobb R.R., and Weller P.F. J. Clin. Invest. 93 (1994) 776
6. Milne A.A.Y., and Piper P.J. Eur. J. Pharmacol. 282 (1995) 243
7. For Rheumatoid Arthritis see:. Seiffge D. J. Rheumatol. 23 (1996) 2086
8. For multiple sclerosis see:. Yednock T.A., Cannon D., and Fritz L.C. Nature 356 (1992) 63
9. Keszthelyi E., Karlik S., Hyduk S., Rice A., Gordon G., Yednock T., and Horner H. Neurology 47 (1996) 1053
10. Lin L.S., Lanza T., Jewell J.P., Liu P., Jones C., Kieczykowski G.R., Treonze K., Si Q., Manior S., Koo G., Tong X., Wang J., Schuelke A., Pivnichny J., Wang R., Raab C., Vincent S., Davies P., MacCoss M., Mumford R.A., and Hagmann W.K. J. Med. Chem. 52 (2009) 3449
11. Hagmann W. Curr. Top. Med. Chem. (2004) 4, 1461
12. Hagmann, William K.; Lin, L. S.; Liu, P.; Mumford, R. A.; Reger, T. S.; Smith, N. D.; Stock, N. S.; Zunic, J. PCT Int. Appl. WO 2005087760 A1, 2008.
13. For kinetic off rate measurements, Jurkat cells were first treated with saturating levels of compound at 37 °C. After one hour incubation, the cells were collected by filtration and washed once with ice-cold binding buffer. Subsequently, cells were re-suspended in the binding buffer containing an excess of [125I]-tracer, and further incubated for increasing periods of time. The cells were collected at different time points, and the radioactivity associated with the cells was measured in a Packard TopCount NXTTM.
14. Hagmann W.K. J. Med. Chem. 51 (2008) 4359
15. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., Deventer S.V., Goldblum R., Despain D., Hogge G.S., and Rutgeerts R. NEJM 353 (2005) 1912
16. Doherty G.A., Yang G.X., Borges E., Tong S., McCauley E.D., Treonze K.M., Riper G.V., Pacholok S., Si Q., Koo G.C., Shah K., Mumford R.A., and Hagmann W.K. Bioorg. Med. Chem. Lett. 13 (2003) 1891
17. See Ref. 6a.
18. Leone D.R., Giza K., Gill A., Dolinski B.M., Yang W., Perper S., Scott D.M., Lee W.-C., Cornebise M., Wortham K., Nickerson-Nutter C., Chen L.L., LePage D., Spell J.C., Whalley E.T., Petter R.C., Adams S.P., Lobb R.R., and Pepinsky R.B. J. Pharmacol. Exp. Ther. 305 (2003) 1150
19. HPLC log D also did not account for differences in binding affinity (all had similar values of 2 at pH 7.3).
20. All the final compounds were greater than 95% ee as measured by chiral HPLC using analytical column (CHIRALCEL OD 10 μ, 4.6 × 250 mm) with heptane and isoproponol/triethylamine as mobile system.